Helsinn terminates oncology collaboration for infigratinib; BridgeBio continues non-oncology development

BridgeBio Pharma, Inc.

QED Therapeutics, BridgeBio subsidiary, received termination notice from Helsinn for infigratinib oncology license agreement.
Helsinn cites commercial considerations for termination of February 2022 agreement.
BridgeBio to continue development of infigratinib for achondroplasia worldwide excluding China, Hong Kong, Macau.
Termination affects commercialization rights for oncology indications worldwide ex-China, Hong Kong, Macau.
No financial terms disclosed; impact on future revenues uncertain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.